Latest Conference Coverage

The chief scientific officer of Sangamo Therapeutics discussed data from 2 of the company’s programs that were presented at ASGCT’s 2023 conference.

The senior scientist at Eterna Therapeutics discussed the company’s numerous presentations at ASGCT’s 2023 conference.

Data trends suggesting stabilization of disease were seen in patients with Tay-Sachs, but more research is needed, especially for those with Sandoff disease.

Updated data from the RESTORE study on MCO-010, Nanoscope Therapeutics' investigational gene therapy, were presented at the 2023 ASGCT meeting.

The vice president of research at Prime Medicine discussed a preclinical study on a novel autologous HSCT treatment that was presented at ASGCT’s 2023 annual meeting.

Following implantation with CellGenTech’s LCAT-GMAC, the patient’s serum LCAT activity increased by approximately 50% of baseline.

ImmTOR induces immune tolerance and may reduce or eliminate Nab formation, allowing potential redosing of gene therapy.

Among 27 evaluated patients with relapsed/refractory B-cell acute lymphoblastic leukemia, 18 achieved a complete response.

The professor at Ohio State University and University of California – San Francisco discussed updated data from a phase 1 study of GDNF gene therapy in patients with PD.

Vitalgen’s gene therapy was generally well-tolerated with no serious adverse events reported.

Bart P. Leroy, MD, PhD, head of the Department of Ophthalmology at the Center for Medical Genetics of Ghent University Hospital, discussed the need to reevaluate the goal posts used to determine whether gene therapies for eye indications come to market.

The cofounder and chief scientific officer of Xcell Biosciences discussed the company’s efforts to introduce new technologies for improving cell therapy development and manufacturing.

The assistant professor of stem cell transplantation at MD Anderson Cancer Center discussed positive data in ccRCC that he believes should excite the solid tumor field as a whole.

Bart P. Leroy, MD, PhD, head of the Department of Ophthalmology at the Center for Medical Genetics of Ghent University Hospital, discussed new real world data regarding Spark Therapeutics’ Luxturna that was presented at ARVO’s 2023 conference.

The director of clinical research at Sierra Eye Associates discussed 4D Molecular Therapeutics’ plans for 4D-150 in both wet AMD and diabetic macular edema.

The cofounder and chief scientific officer of Xcell Biosciences discussed the company’s manufacturing-focused approach to overcoming the challenges of the solid tumor microenvironment.

The cell therapy field applications staff scientist at ThermoFisher discussed advantages of the company’s DynaCellect system.

Bart P. Leroy, MD, PhD, head, Department of Ophthalmology, Center for Medical Genetics, Ghent University Hospital, discussed the ongoing efforts to verify the efficacy of Spark Therapeutics’ Luxturna.

The director of clinical research at Sierra Eye Associates discussed the latest results from a clinical trial evaluating 4D Molecular Therapeutics’ gene therapy, 4D-150, that were presented at ARVO’s 2023 conference.

The single-administration allogeneic cell therapy has shown positive safety—and signs of efficacy—in preliminary data from the first 2 patients dosed with the Neurona Therapeutics’ product.

Arnaud Lacoste, PhD, the chief scientific officer of Aurion Biotech, discussed AURN001, a corneal endothelial cell therapy that was recently approved in Japan, and had a nonclinical data read out at ARVO 2023.

The head of the Department of Ophthalmology at the Center for Medical Genetics at Ghent University Hospital discussed the need to reevaluate requirements for regulatory approval for ophthalmology gene therapies.

Krystal Biotech's B-VEC was well-tolerated and the treated patient experienced significant improvement in visual acuity.

The cofounder and chief scientific officer of Xcell Biosciences discussed the company’s research with a newly developed assay method that was presented at AACR’s 2023 conference.

The head of immunology at Turn Biotechnologies discussed preclinical data demonstrating proof-of-concept with the company’s epigenome reprogramming platform.

The cofounder and chief executive officer of NKILT Therapeutics discussed new preclinical data presented at WOCTC.

The head of the Department of Ophthalmology at the Center for Medical Genetics, Ghent University Hospital, discussed the main takeaways of a post-marketing study on the gene therapy.

The chief medical officer of Trisalus Life Sciences discussed the company’s PEDD system and SD-101.